AGO Germany   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Hamburg Germany (1993)

Organization Overview

First Clinical Trial
1999
NCT00006453
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

AGO, ASCO, DKG | AGO-OVAR, AGO Ovarian Cancer Study Group | AGO-OVAR, Ovarian Cancer Study Group, Germany; Ubbo-Emmius-Klinik gGmbH Aurich, Germany | AGO Research GmbH | AGO Study Group | AGO Study Group (Study Group of the Arbeitsgemeinschaft Gynaekologische Onkologie) | AGO-TraFo